FLORA Ventures
VC Fund
Tel Aviv-jaffa, Israel
FLORA Ventures (www.floravc.com) is a new early-stage VC fund that is identifying, backing and partnering with the best purpose-led entrepreneurs redefining the $8T AgriFood & Sustainability industries, to make food that is good for people, and kind to the planet. The fund’s investment thesis is focused on the intersection of the AgriFoodindustry with Planetary & Human Health, all underpinned by deep-tech. FLORA Ventures is accessing a proprietary deal-flow, and we are supporting our portfolio companies with our hands-on deep industry know-how, global network and access to smart capital. The fund is managed by experienced and industry expert General Partners, and backed by leading Institutional and Strategic Limited Partner investors.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries FLORA Ventures invests in
Stages FLORA Ventures invests in
Countries FLORA Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Medical 1 (33%)
- Hospital 1 (33%)
- Health Care 1 (33%)
- Biotechnology 1 (33%)
- Medical Device 1 (33%)
Stage
- Seed 1 (33%)
- Pre-Seed 1 (33%)
- Series A 1 (33%)
Country
- Germany 1 (33%)
- United Kingdom 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gil Horsky
Founding Managing Partner
|
Founding Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lembas
|
Lembas is a foodtech startup that has developed "GLP-1 Edge," a patent-pending peptide ingredient designed to naturally boost the GLP-1 hormone, which helps regulate appetite and metabolism for weight management. Using AI-driven discovery and licensed technology from Tel Aviv University, Lembas offers this peptide powder as abusiness-to-business ingredient for food and supplement brands, providing a science-backed, non-pharmaceutical alternative to weight loss drugs with no reported side effects | $3.6M / Pre-Seed / Jun 10, 2025 | |
OlsAro
|
OlsAro produces salt-tolerant crops. | $2.7M / Seed / Apr 16, 2024 | |
4TEEN4 Pharmaceuticals
|
4TEEN4 Pharmaceuticals GmbH is a biopharmaceutical company developing Procizumab, a humanized antibody targeting human Dipeptidyl Peptidase 3 (DPP3) for the treatment of acute cardiovascular diseases. | $6.9M / Series A / Jun 29, 2023 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does FLORA Ventures invest in?
FLORA Ventures invests primarily in Medical, Hospital and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact FLORA Ventures?
Public channels for FLORA Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at FLORA Ventures?
The team at FLORA Ventures includes Gil Horsky (Founding Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
